Published in J Natl Cancer Inst on May 12, 2009
Adaptive trial designs: a review of barriers and opportunities. Trials (2012) 1.91
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
A statistical evaluation of dose expansion cohorts in phase I clinical trials. J Natl Cancer Inst (2015) 1.54
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol (2013) 1.30
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res (2012) 1.18
Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys (2010) 1.14
Interplay of priors and skeletons in two-stage continual reassessment method. Stat Med (2012) 1.07
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood (2012) 1.07
Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol (2013) 1.04
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist (2011) 1.02
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res (2014) 1.01
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res (2014) 0.98
Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials (2014) 0.95
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clin Cancer Res (2012) 0.94
Implementation of adaptive methods in early-phase clinical trials. Stat Med (2016) 0.94
Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. Kennedy Inst Ethics J (2010) 0.94
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs (2012) 0.93
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer (2010) 0.92
Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol (2016) 0.91
Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemother Pharmacol (2013) 0.90
Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS One (2012) 0.90
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol (2014) 0.90
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol (2015) 0.89
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol (2011) 0.88
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Invest New Drugs (2014) 0.87
Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Stat Med (2013) 0.87
Targeting cancer with peptide aptamers. Oncotarget (2011) 0.87
Escalation with overdose control using time to toxicity for cancer phase I clinical trials. PLoS One (2014) 0.87
Approaches for informing optimal dose of behavioral interventions. Ann Behav Med (2014) 0.86
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol (2011) 0.85
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann Oncol (2015) 0.85
A Phase I/II trial design when response is unobserved in subjects with dose-limiting toxicity. Stat Methods Med Res (2012) 0.85
Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities. Stat Med (2011) 0.85
Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. BMC Cancer (2013) 0.84
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain (2014) 0.84
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res (2015) 0.83
A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemp Clin Trials (2015) 0.83
The motivations and methodology for high-throughput PET imaging of small animals in cancer research. Eur J Nucl Med Mol Imaging (2012) 0.83
From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst (2013) 0.82
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer (2014) 0.82
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol (2017) 0.81
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. PLoS One (2011) 0.81
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy. Clin Cancer Res (2016) 0.81
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks. Int J Mol Sci (2014) 0.81
Phase I trials of antitumour agents: fundamental concepts. Ecancermedicalscience (2015) 0.80
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy. PLoS One (2014) 0.80
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs (2014) 0.80
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer (2014) 0.79
The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol (2015) 0.79
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol (2014) 0.79
Bayesian adaptive designs in single ascending dose trials in healthy volunteers. Br J Clin Pharmacol (2014) 0.79
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Invest New Drugs (2012) 0.79
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res (2016) 0.79
Beyond the margins: real-time detection of cancer using targeted fluorophores. Nat Rev Clin Oncol (2017) 0.78
Early phase clinical trials to identify optimal dosing and safety. Mol Oncol (2014) 0.78
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer (2016) 0.78
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol (2014) 0.78
Re: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 0.78
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics (2013) 0.78
Phase I trials of targeted anticancer drugs: a need to refocus. Nat Rev Drug Discov (2012) 0.78
Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol (2017) 0.77
Approaches to modernize the combination drug development paradigm. Genome Med (2016) 0.77
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma. Bladder Cancer (2016) 0.77
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer (2015) 0.77
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients. Invest New Drugs (2014) 0.77
Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication. Death Stud (2015) 0.77
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
Bridging the gap: a review of dose investigations in paediatric investigation plans. Br J Clin Pharmacol (2014) 0.77
Improving access to novel agents for childhood leukemia. Cancer (2015) 0.76
Innovations for phase I dose-finding designs in pediatric oncology clinical trials. Contemp Clin Trials (2016) 0.76
Treatment of faecal incontinence using allogeneic-adipose-derived mesenchymal stem cells: a study protocol for a pilot randomised controlled trial. BMJ Open (2016) 0.75
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. Cancer Invest (2011) 0.75
Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants: study protocol for a randomised controlled trial. Trials (2016) 0.75
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget (2015) 0.75
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials. PLoS One (2016) 0.75
How to keep high-risk studies ethical: classifying candidate solutions. J Med Ethics (2016) 0.75
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. Oncology (2012) 0.75
Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials. J Clin Oncol (2016) 0.75
A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials. Stat Med (2016) 0.75
Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group. Neurol Med Chir (Tokyo) (2016) 0.75
Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. J Clin Neurosci (2013) 0.75
Advances in Statistical Approaches Oncology Drug Development. Ther Innov Regul Sci (2014) 0.75
Dose-finding designs for trials of molecularly targeted agents and immunotherapies. J Biopharm Stat (2017) 0.75
An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016). J Gynecol Oncol (2016) 0.75
A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model. PLoS One (2016) 0.75
Examining the effect of teleconferences on oncology phase 1 trials. J Cancer (2013) 0.75
TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology. Stat Biosci (2015) 0.75
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer (2017) 0.75
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials. Stat Med (2017) 0.75
Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data. BMC Cancer (2016) 0.75
How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis? Leukemia (2016) 0.75
Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements. Mol Ther (2012) 0.75
Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma. PLoS One (2017) 0.75
Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open (2017) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990) 10.19
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics (2000) 5.50
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst (1997) 4.60
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
Design and analysis of phase I clinical trials. Biometrics (1989) 4.31
Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med (1998) 4.19
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol (1991) 3.96
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol (2002) 3.53
Dose-finding based on efficacy-toxicity trade-offs. Biometrics (2004) 3.46
Some practical improvements in the continual reassessment method for phase I studies. Stat Med (1995) 3.43
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol (2004) 3.40
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol (2001) 2.82
A comparison of two phase I trial designs. Stat Med (1994) 2.71
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol (2008) 2.46
Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol (1998) 2.35
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst (2004) 2.26
Dose-finding with two agents in Phase I oncology trials. Biometrics (2003) 2.23
An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med (2006) 2.16
Phase I clinical trial design in cancer drug development. J Clin Oncol (2000) 2.14
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
Dose selection in phase I studies: why we should always go for the top. J Clin Oncol (2008) 2.08
Isotonic designs for phase I trials. Control Clin Trials (2001) 2.00
Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics (2006) 1.95
Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep (1986) 1.91
Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials (2007) 1.85
Phase I clinical and pharmacokinetic study of taxol. Cancer Res (1987) 1.74
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs (1991) 1.67
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol (2003) 1.60
Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med (2005) 1.59
Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat (1994) 1.54
A parallel phase I/II clinical trial design for combination therapies. Biometrics (2007) 1.52
An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med (1995) 1.49
Improved up-and-down designs for phase I trials. Stat Med (2003) 1.49
Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics (2007) 1.48
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol (1992) 1.46
Adaptive design improvements in the continual reassessment method for phase I studies. Stat Med (1999) 1.39
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.34
Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol (2006) 1.33
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol (1998) 1.32
Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med (1991) 1.29
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med (2007) 1.29
Sequential continual reassessment method for two-dimensional dose finding. Stat Med (2008) 1.28
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol (2003) 1.27
An evaluation of phase I clinical trial designs in the continuous dose-response setting. Stat Med (2001) 1.24
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer (2007) 1.21
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst (1991) 1.21
Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol (1993) 1.20
A random walk rule for phase I clinical trials. Biometrics (1997) 1.15
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res (2001) 1.15
Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett (1985) 1.13
Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst (1992) 1.12
Phase I trial design: are new methodologies being put into practice? Ann Oncol (1996) 1.08
Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol (2007) 1.08
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer (2007) 1.07
Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer (1999) 1.05
Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol (2008) 1.05
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother (1986) 1.04
Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst (1990) 1.02
Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study. Eur J Cancer (2006) 0.99
Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests. Biometrics (2007) 0.96
What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J Clin Oncol (2006) 0.94
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res (1998) 0.93
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Clin Cancer Res (2002) 0.87
The accelerated biased coin up-and-down design in phase I trials. J Biopharm Stat (2004) 0.85
The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. Ann Oncol (1992) 0.80
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
The statins as anticancer agents. Clin Cancer Res (2003) 3.36
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol (2005) 3.34
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol (2005) 2.83
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials (2009) 2.79
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Nasopharyngeal carcinoma: the next challenges. Eur J Cancer (2010) 2.04
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer (2006) 2.04
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Designing transformative clinical trials in the cancer genome era. J Clin Oncol (2013) 1.79
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol (2003) 1.71
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol (2008) 1.70
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol (2005) 1.69
Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila) (2009) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res (2006) 1.63
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer (2009) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst (2010) 1.59
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst (2007) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther (2005) 1.57
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol (2007) 1.53
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer (2012) 1.49
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer (2006) 1.45
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res (2008) 1.42
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer (2006) 1.41
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer (2006) 1.36
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer (2006) 1.33
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res (2011) 1.33
Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev Res (Phila) (2012) 1.33
Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog (2010) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) (2008) 1.32
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res (2012) 1.32
Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol (2005) 1.31
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther (2007) 1.29
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol (2006) 1.29
A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics (2006) 1.28
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol (2012) 1.28
Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol (2007) 1.28
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope (2005) 1.27
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res (2007) 1.26
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26